Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Publisher:
New England Journal of Medicine
Date published:
2013
Record type:
Journal Title:
The New England Journal of Medicine
Source:
The New England Journal of Medicine, Vol. 369, No. 2, July 11, 2013, pp. 134-144
Subject:
Abstract:
Antibodies to PD-1 appeared to unblock T-cell responses to melanoma in a sizeable fraction of patients with antitumor responses, some of which were long-lasting. Toxic effects were mainly grade 1 or 2 fatigue, rash, pruritus, and diarrhea.
Language:
Catagory URL:
CITATION: Hamid O. [etal]. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma . : New England Journal of Medicine , 2013. The New England Journal of Medicine, Vol. 369, No. 2, July 11, 2013, pp. 134-144 - Available at: https://library.au.int/safety-and-tumor-responses-lambrolizumab-anti–pd-1-melanoma-3